The safety profile of topical GHK-Cu is well-established across decades of use and multiple clinical trials
GLP-1 receptor agonists represent a hard-earned pharmacological breakthrough, offering potent glucose control and unprecedented weight loss
However, PSPH ser/gly pathway enzyme genetic aberrations are not acknowledged as important drivers of GBM because of the close proximity of EGFR (chr7:5501901755211628) to PSPH (chr7:5601105156051604), which is a common driver oncogene in GBM [47,48,49]
Angelova-Fischer I, Rippke F, Fischer TW, Neufang G, Zillikens D
Adding it to existing insulin therapy or impaired glucose handling can produce unpredictable, severe hypoglycemia
JOIN US.